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Aims: While strong correlations exist between medication adherence and health economic 
outcomes in type 2 diabetes, current economic analyses do not adequately consider them. We 
propose a new approach to incorporate adherence in cost-effectiveness analysis.
Methods: We describe a theoretical approach to incorporating the effect of adherence when 
estimating the long-term costs and effectiveness of an antidiabetic medication. This approach 
was applied in a Markov model which includes common diabetic health states. We compared 
two treatments using hypothetical patient cohorts: injectable insulin (IDM) and oral (OAD) 
medications. Two analyses were performed, one which ignored adherence (analysis 1) and one 
which incorporated it (analysis 2). Results from the two analyses were then compared to explore 
the extent to which adherence may impact incremental cost-effectiveness ratios.
Results: In both analyses, IDM was more costly and more effective than OAD. When adherence 
was ignored, IDM generated an incremental cost-effectiveness of $12,097 per quality-adjusted 
life-year (QALY) gained versus OAD. Incorporation of adherence resulted in a slightly higher 
ratio ($16,241/QALY). This increase was primarily due to better adherence with OAD than with 
IDM, and the higher direct medical costs for IDM.
Conclusions: Incorporating medication adherence into economic analyses can meaningfully 
influence the estimated cost-effectiveness of type 2 diabetes treatments, and should therefore 
be   considered in health care decision-making. Future work on the impact of adherence on 
health   economic outcomes, and validation of different approaches to modeling adherence, is 
warranted.
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Introduction
Type 2 diabetes (T2D) presents a substantial health economic burden globally, and its 
prevalence and costs are only forecasted to increase in the coming years.1–3 Medication 
adherence, especially for patients with chronic diseases such as T2D, has long been 
viewed as a critical lever for improving outcomes and containing costs. Recent studies 
conclude that more than $100 billion is spent each year in the US on hospitalizations that 
could have been avoided with optimal medication adherence.4 Indeed, growing evidence 
suggests that suboptimal T2D medication adherence eventually results in higher HbA1c 
levels, complication rates, and costs. Conceptual frameworks have been developed to 
describe these interrelations and their effect on reimbursement policies.5–8
In order to make appropriate judgments about resource allocation and cost-sharing 
(namely involving pharmaceuticals), decision-makers have progressively relied on 
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  diabetes treatment on clinical outcomes, health events, 
  quality-of-life (QoL), and costs is often mathematically mod-
eled since notable complications may occur years after onset 
of diabetes.9 However, current models used in T2D economic 
analysis do not adequately address or explain incorporation 
of real-world   factors which influence medication adherence. 
These factors are wide-ranging and include patient prefer-
ences and behaviors, health care system factors, practice 
guidelines and patterns, and treatment characteristics.8,10 
The   exclusion of these factors can lead to inaccurate estimates 
on the cost-effectiveness of diabetes therapies, and thereby 
result in misinformed reimbursement decisions affecting 
patient access to treatment.
Several diabetes medications now in development have 
been criticized for being too similar to each other and not 
offering significant clinical benefit over existing therapies.11 
However, most of these new therapies and delivery systems 
differ greatly in other “nonclinical” ways, such as their route 
of administration, dosing schedule/convenience, and device 
ergonomics, all of which may influence patient preferences 
and behaviors (hence, medication adherence).5,6,8 This high-
lights the increasingly important role that adherence could 
play in the health technology assessment of new anti-T2D 
therapies as they reach the market. In particular, this is note-
worthy for injectable diabetes medications (IDM) (ie, insulin) 
versus oral antidiabetic (OAD) medications, since needle 
phobia, multiple daily injections, and varied dosing schedules 
(eg, meal timing) are inherently associated with IDM and 
may adversely affect adherence.5
There is substantial opportunity to improve the methods 
used to estimate the cost-effectiveness of T2D medications 
by considering medication adherence.8,9 The objective of 
this study was to develop and apply an approach to integrate 
adherence in an economic model of diabetes.8 In doing so, 
we compared the cost-effectiveness of IDM versus OAD 
before and after adjustment for adherence, hypothesizing that 
incorporation of medication adherence would reduce the cost-
effectiveness of IDM versus OAD, since patients on IDM 
generally exhibit poorer adherence than OAD patients.
Research design and methods
We developed a novel approach to modeling medication adher-
ence among T2D patients using conventional health economic 
techniques and software (Microsoft Excel and TreeAge Pro 
2009). To test our approach, 2 separate   economic analyses 
were conducted in a Markov/Monte Carlo format to provide 
a preliminary estimate of the impact of medication adherence 
on incremental cost-effectiveness ratios (ICERs):
•	 Analysis 1: Base-case modeling of IDM vs OAD
•	 Analysis 2: Adherence-adjusted modeling
Markov modeling in health care consists of developing 
a structure of a specified number of health states related 
to a given disease. Over time, patients will have a certain 
chance (or transition probability) to move from one health 
state to   another.12 This approach is particularly well suited 
for   modeling chronic diseases, such as T2D, where   numerous 
health states/complications exist and are repeatable,   previous 
history of complications may impact future events, and where 
a long-term perspective for downstream outcomes is relevant. 
Monte Carlo simulations commonly serve as the analytic/
mathematic engine to a Markov structure, as was done in 
our analyses. This allows for transition probabilities into 
and out of health states to be applied, including sensitivity 
analysis, whereby assumptions on reasonable variation for 
transition probabilities and the effects of random error may 
be accounted for.13
Base case model
The model we developed consists of major health states 
that define the natural history of T2D and are consistent 
with those seen in previous models (see Figure 1).10,14 These 
states include the various diabetes complications, such as 
end-stage renal disease (ESRD), lower-extremity amputation, 
cardiovascular and coronary artery disease (CVD/CAD), 
nephropathy, stroke, neuropathy, retinopathy, and major 
hypoglycemia.
In this model, patients receive either IDM (insulin in 
our example) or OADs, chosen as mutually exclusive com-
parators because of the inherent differences between them 
which readily impact adherence. Patients on both therapies 
begin at a baseline HbA1c that is either ,7% or $7%, and 
through subsequent annual iterations, may (1) remain in 
a ‘healthy’ state with controlled (,7%) or uncontrolled 
($7%) HbA1c, (2) progress between T2D complication 
states (with controlled or uncontrolled HbA1c), or (3) die. 
Probabilities for patients to move from one complication 
state to another are based on HbA1c over time, since patients 
with controlled HbA1c are much less likely to develop 
complications.10,14 Treatment effects (mean of –1.2% HbA1c 
and –0.8% HbA1cfor IDM and OAD, respectively, to reflect 
greater potency of insulin use) were applied to assumed 
baseline HbA1c means of 8.1% and 6.8% for patients mod-
eled to HbA1c $7% and ,7%, respectively.14,15 An annual 
increase in HbA1c – or “creep up” effect – of + 0.14% per 
year was applied to initial levels of glycemic control to 
reflect the natural progression of underlying biological Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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mechanisms affecting glycemic control over time, such 
as beta-cell loss and reduced insulin sensitivity.10,14 In the 
base case scenario, approximately 50% fewer IDM patients 
were, on average, likely to have baseline HbA1c ,7% versus 
OAD patients, as those who are prescribed IDM frequently 
have further progressed, and/or more difficult to control, 
T2D. 14–16 In both analysis 1 and analysis 2, the Death state 
may be transitioned to after any/all previous health state(s) 
and reflects all-cause mortality as well as adjustment for 
severity of T2D/CVD risk over time.
A lifetime (up to 35-year horizon), US third-party payer 
perspective was taken starting from the time of T2D treatment 
initiation.10 Cohort characteristics and transition probabi  lities 
were derived from large epidemiologic studies, clinical trials, and 
recent national surveillance data.10,14,15 Modeled output included 
life expectancy (LE), quality-adjusted life expectancy (QALE), 
cumulative incidence of T2D   complications, direct medical and 
pharmacy costs, total lifetime costs, and ICERs.
simulated cohorts and assumptions
The demographic and clinical characteristics used 
in the patient cohorts reflected those of typical US 
T2D   populations, including the percentage of patients 
receiving specific OADs and IDM, the percentage of 
patients with baseline HbA1c ,7% (for OADs 46.6%, 
for IDM 26.8%), age (mean of 51.1 years), gender 
(51.6% male), race/ethnicity (62.1% white, 17.4% 
black, 15.4% Hispanic, 5.1% other), presence of risk 
factors (eg, smokers 18.8%), and presence of preexisting 
complications.10,14–16
The magnitude and duration of mean treatment effects 
remained consistent among IDM and OAD subclasses, and 
were extracted from large, long-term epidemiologic studies 
and literature reviews.10,14,15 Applied risk factors included 
BMI, total cholesterol, systolic blood pressure, triglycerides, 
and smoking.10
QoL utilities and disutilities for T2D health states were 
derived from previous studies.10,14 Mean pharmacy costs 
based on average 30-day wholesale price, and direct medical 
costs such as hospitalizations, were collected from published 
data and inflated to 2009 USD.5,6,10,15,17 Of the patients who 
received IDM, it was assumed that 70% of them were given 
human insulin and 30% analog insulin. Within the OAD 
cohort, 70% of the patients were assumed to receive generic 
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Figure 1 Base case model of fundamental T2D health states.
Notes: *Death = All-cause mortality adjusted for T2D/CVD severity.
Abbreviations: iDM, injectable diabetes medication; OAD, oral antidiabetic drug; CVD, cardiovascular disease; CAD, coronary artery disease; esrD, end-stage renal disease.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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metformin ± sulfonylurea, and 30% nongeneric thiazolidin-
ediones. This was done in analyses 1 and 2 to incorporate 
consistency for drug costs, and to approximate the use of 
generics in a real-world US scenario.18,19 A 3% discount 
rate for future costs and health was applied as a base case 
assumption; however, a range of 0%–6% was allowed during 
sensitivity analyses to address a range of variation in present 
value of benefits over time.10
Adherence-adjusted model  
and theoretical approach
As depicted in Figure 2, adjustments for adherence involved 
revisions to the degree of modeled glycemic control, risks of 
subsequent diabetes complications, and costs using current 
evidence on the impact of real-world medication adherence. 
Applied rates of adherence were primarily determined using 
medication possession ratios (MPR), and were derived 
from large observational studies.5–7,18–22 Just as the target 
of HbA1c ,7% was applied to model the impact of gly-
cemic control in analysis 1, MPR ($80%) was added and 
applied to model the influence of optimal versus suboptimal 
(MPR , 80%) adherence in analysis 2. New health states 
were created, where categorical levels of MPR were combined 
with categorical HbA1c control, thereby enabling MPR to 
directly influence the likelihood of a patient moving to, and 
remaining in, either of the HbA1c categories (HbA1c , 7% 
or HbA1c $ 7%), and hence experience downstream T2D 
complications and costs. For example, recent data suggest 
that OAD and IDM patients with MPR $ 80% are more 
likely to achieve HbA1c , 7%, have reduced incidence of 
hypoglycemia and related resource use, and incur lower 
health care costs.5,7,18–22
Specifically, revised transition probabilities in the 
  adherence-adjusted model include means and distributions 
regarding adherence to anti-T2D treatment, likelihood of 
  achieving HbA1c , 7%, and likelihood of major hypoglycemia. 
Up to 13% and 6% of patients on OADs and IDM, respectively, 
were allowed to exhibit MPR $ 80% (ranges: 36%–93% OADs, 
54%–86% IDM). The chance of achieving target HbA1c was 
approximately 28% greater for patients with MPR $ 80%, and 
the chance of major hypoglycemia was 64% lower for patients 
with MPR $ 80% (74% chance overall, but only 47% chance 
for optimal adherence; OR: 0.36, P , 0.01).5,7,18–22 Medication 
adherence in both groups was modeled to worsen over time, 
at –0.3% per year.6,14
statistical and sensitivity analyses
Probabilistic sensitivity analyses, wherein a range of distributions 
(uncertainty) for values of all input parameters are applied 
simultaneously, were conducted using cohort-level Monte Carlo 
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Figure 2 Adherence-adjusted approach at modeling T2D.
Notes: *Death = All-cause mortality adjusted for T2D/CVD severity.
Abbreviations: iDM, injectable diabetes medication; OAD, oral antidiabetic drug; CVD, cardiovascular disease; CAD, coronary artery disease; esrD, end-stage renal 
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simulation and bootstrapping. The   progression of T2D was 
simulated in a 1000 × 1000   manner (each cohort of 1000 patients 
was simulated 1000 times), producing individual candidate boot-
strap samples. The average costs and health for each cohort were 
first calculated, followed by an analysis of the 1000 average values 
(one per cohort). This resulted in means and standard deviations of 
the incremental costs, complication incidences, LE, and QALE for 
both IDM and OAD. Lastly, these means and standard deviations 
were calculated and compared for IDM versus OAD.
Results
Base case scenario: analysis 1
IDM use resulted in a longer LE (+0.56 years) and QALE 
(+0.92 years) than OAD use (Table 1). IDM also reduced 
the rates of major hypoglycemia, ESRD, CVD/CAD, 
nephropathy, and neuropathy.
Although IDM resulted in greater clinical effective-
ness, IDM patients also incurred higher costs (by $11,166) 
than OAD patients, with pharmacy costs accounting for the 
  majority ($8,768) of this difference. The ICER for IDM 
versus OAD was $12,097 per quality-adjusted life-year 
(QALY) gained, using total health care costs.
Adherence-adjusted model: analysis 2
After adjustment for adherence, IDM still led to a longer LE 
and QALE than OADs by +0.331 and +0.675 years, respec-
tively, although the differences observed between IDM and 
OADs were smaller than without adjustment for adherence. 
Table 1 summary of modeled results: iDM vs OADs*
IDM vs OADs IDM OADs  Difference
Analysis 1
Clinical outcomes, years
  Life expectancy (discounted) 16.376 (0.18) 15.815 (0.17) 0.561 (0.01)
  Quality-adjusted life expectancy 10.554 (0.10) 9.631 (0.09) 0.923 (0.01)
Complication rates, cumulative incidence, % (sD)
  end-stage renal disease 17.6 (1.1) 18.1 (1.2) -0.5 (0.1)
  Amputation 13.4 (1.1) 13.8 (1.0) -0.4 (0.1)
  CVD/CAD 22.1 (1.3) 22.7 (1.5) -0.6 (0.2)
  nephropathy 36.3 (1.6) 37.2 (1.6) -0.9 (0.0)
  stroke 9.1 (0.9) 9.4 (1.0) -0.3 (0.1)
  neuropathy 46.3 (1.6) 47.8 (1.5) -1.5 (0.1)
  retinopathy 19.9 (1.3) 19.8 (1.3) 0.1 (0.0)
  Major hypoglycemia 63.8 (1.9) 55.5 (1.8) 8.3 (0.1)
Cost outcomes, Us$
  Direct medical costs 241,304 (8122) 238,906 (8218) 2,398 (96)
  Pharmacy costs 60,551 (2231) 51,783 (2004) 8,768 (227)
  Total lifetime costs 301,855 (8933) 290,689 (8690) 11,166 (243)
$/QALY (iDM vs OADs) 12,097
Analysis 2
Clinical outcomes, years
  Life expectancy (discounted) 16.562 (0.18) 16.231 (0.17) 0.331 (0.01)
  Quality-adjusted life expectancy 10.848 (0.10) 10.173 (0.01) 0.675 (0.09)
Complication rates, cumulative incidence, % (sD)
  end-stage renal disease 17.0 (1.1) 17.3 (1.0) -0.3 (0.1)
  Amputation 13.3 (1.0) 13.6 (1.2) -0.3 (0.2)
  CVD/CAD 21.9 (1.4) 22.1 (1.3) -0.2 (0.1)
  nephropathy 34.7 (1.4) 35.0 (1.4) -0.3 (0.0)
  stroke 8.8 (0.8) 8.9 (0.8) -0.1 (0.0)
  neuropathy 45.8 (1.7) 46.6 (1.7) -0.8 (0.0)
  retinopathy 18.5 (1.2) 18.2 (1.1) 0.3 (0.1)
  Major hypoglycemia 59.8 (1.8) 48.4 (1.6) 11.4 (0.2)
Cost outcomes, Us$
  Direct medical costs 244,112 (8034) 241,037 (8026) 3,075 (8)
  Pharmacy costs 62,788 (2319) 54,900 (1996) 7,888 (323)
  Total lifetime costs 306,900 (9155) 295,937 (8716) 10,963 (439)
$/QALY (iDM vs OADs) 16,241
Abbreviations: iDM, injectable diabetes medication; OAD, oral antidiabetic drug; CVD, cardiovascular disease; CAD, coronary artery disease; QALY, quality-adjusted life-year.
* Means with standard deviations (sD) from 1000 patients in each of 1000 cohort simulations are provided.Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
288
Cobden et al
While gaps between IDM and OADs in the incidence rates of 
some complications shrank, the rate of major hypoglycemia 
increased.
Total costs remained higher for IDM than for OAD 
(+$10,963) after incorporating adherence. The ICER of IDM 
versus OAD increased to $16,241 per QALY gained, again 
using total costs.
impact of adherence on modeled output
Adjustment for adherence affected the differences between 
IDM and OAD treatment in a number of ways,   including 
(1) generating smaller differences in LE and QALE; 
(2) smaller differences in all complication rates except for 
major hypoglycemia, which increased by 3.1%; and (3) a 
34.3% higher ICER for IDM versus OADs ($16,241/QALY 
versus $12,097/QALY).
Comparing analysis 2 with analysis 1, LE and QALE 
for OADs improved 45% and 54% more than for IDM, and 
the relative difference in rates of ESRD, amputation, and 
neuropathy between IDM and OADs narrowed by 40%, 
25%, and 53%, respectively, and CVD/CAD, nephropathy, 
and stroke by 2/3 each.
sensitivity analyses
Probabilistic simulations did not meaningfully alter ICERs 
for IDM versus OADs in analysis 1 or 2, indicating a suffi-
cient approach at limiting modeled uncertainty. Our base case 
model generated a range of ICERs from $7,155 to $18,300/
QALY, and our revised model generated a range of $11,217 
to $23,892/QALY.
Discussion
Utilizing a Markov model of fundamental T2D health states, we 
specifically aimed to (1) describe a new approach for modeling 
medication adherence, and (2) illustrate its impact on estimated 
cost-effectiveness. Our simulations demonstrated that adherence 
may be meaningfully incorporated into comparative economic 
analysis through its associations with level of glycemic control, 
which has an important impact on the risk of downstream dia-
betes complications (eg, major hypoglycemia) and costs.
In the adherence-adjusted model (analysis 2), we obser-
ved an increased ICER, resulting from several sources. Most 
notably, LE and QALE increased by up to 54% more for 
OADs than for IDM (although both cohorts saw slightly 
higher values than in analysis 1). The main reason for this 
effect was the increased number of patients   modeled to 
HbA1c , 7% after stratifying by MPR, and thus   experiencing 
less T2D complications and associated QoL disutilities 
(ie, the range of applied MPR estimates caused up to 13% 
and 6% more OAD and IDM patients to have greater like-
lihood of HbA1c , 7% in analysis 2). Secondly, although 
the differences for most complication rates between IDM 
and OADs decreased after adjustment for adherence, the 
difference in major hypoglycemia rates increased by 37%. 
Thirdly, a greater proportion of IDM lifetime costs were 
driven by direct medical costs, as opposed to pharmacy 
costs, after adjustment for adherence. These changes in 
modeled results likely occurred because more OAD patients 
were categorized into MPR $ 80% than IDM patients, and 
they therefore experienced less risk of major hypoglycemia 
(and related QoL disutility) as well as a greater chance of 
HbA1c ,7%, resulting in fewer complications and increased 
QoL over time. Similarly, a higher frequency of MPR , 
80% amongst IDM patients meant a higher risk of hypo-
glycemia, as well as a higher risk of other complications 
and higher costs. Furthermore, a balancing effect between 
greater treatment potency and overall poorer adherence 
likely occurred for IDM versus OADs. In this way, the 
greater HbA1c-lowering effect of insulin, which would 
reduce complication rates and thereby improve health out-
comes, may have been partially offset by a higher frequency 
of MPR , 80% and HbA1c $ 7%, and thus a higher starting 
HbA1c level in the first year of treatment.
It is important to note several limitations to our model-
ing approach. Although the simulated diabetes population 
in our analyses was intended to represent a typical US T2D 
population, our assumptions regarding transition probabili-
ties, actual pharmacy costs, and QoL values may not have 
fully achieved this. However, it is important to note that the 
primary goal of this study was to illustrate how adherence 
may be included in diabetes health economic models, and 
to then estimate the impact of adherence on ICERs. Our 
goal was not to evaluate the cost-effectiveness of a specific 
treatment, nor to focus on a specific population. In keeping 
the treatments and simulated populations constant between 
analyses 1 and 2, the isolated effect on cost-effectiveness 
of modeled adherence was revealed. Although outside the 
scope of our current analysis, it is important to recognize 
the increasing evidence that T2D disproportionally affects 
minority subpopulations in the US. It would therefore be 
interesting and worthwhile to model the impact of adher-
ence in these subpopulations in a future study. The choice to 
compare IDM with OADs as hypothetical therapies occurred 
solely because they clearly differ in treatment modalities 
which may impact degree of adherence. Although our 
model could have allowed switches to occur between OADs Patient Preference and Adherence 2010:4 submit your manuscript | www.dovepress.com
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and IDM throughout a patient’s life, we chose not to allow 
these switches, since it would have complicated the model 
and would not have contributed to illustrating the potential 
effect of incorporating adherence. That is, the incorpora-
tion of treatment changes would have generated a “mixed 
effect” of the impact of medication adherence and the rela-
tive effectiveness of different treatment strategies at various 
points in a patient’s disease progression. Thirdly, transition 
probabilities in the adherence-adjusted model are based 
largely on observational studies, which provide statistical   
associations that do not necessarily reflect cause–effect 
relationships. This underscores the importance of future work 
aimed at (1) developing more robust evidence on correla-
tions between adherence and T2D outcomes, (2) identifying 
novel data sources and analytic techniques for observational, 
real-world research, and (3) further validation of different 
modeling approaches.
Modeling techniques worth exploring in future analyses 
include application of differential- and regression-based 
equations where adherence is a continuous parameter (vari-
able) that influences glycemic control and complication 
rates over time, as opposed to a categorical approach, as 
was done in this study. Additionally, deterministic sensi-
tivity analyses using point estimates could be performed 
to gain more direct insight into how much influence a 
specific input variable has, as opposed to allowing mul-
tiple parameters to vary simultaneously in a probabilistic 
sensitivity analysis. Lastly, it is important to note that 
although our adherence-adjusted approach produced an 
ICER that was approximately 34% higher than the ICER 
without adherence adjustment, IDM remained well within 
conventional thresholds of what is considered “good value 
for money”, especially when considering preferences and 
trade-offs in health care from a US societal perspective 
(up to $297,000/QALY).23
Medication adherence is an important issue in chronic 
disease and, in particular, diabetes care. However,   current 
economic models of diabetes pay too little attention to 
adherence, even though it may meaningfully influence the 
estimated cost-effectiveness of diabetes medicines. As new 
data and analytic techniques become available, and as new 
T2D compounds are commercialized, this will become 
increasingly important to inform health care decision-making 
for real-world settings.
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